<DOC>
	<DOCNO>NCT01123044</DOCNO>
	<brief_summary>The aim study assess transplantation cultivate corneal epithelial stem cell could restore vision patient severe ocular surface disorder favourable safety profile warrant comparative study .</brief_summary>
	<brief_title>Transplantation Cultivated Corneal Epithelial Sheet Patients With Ocular Surface Disease</brief_title>
	<detailed_description>Objectives : Efficacy : To determine efficacy cultivate corneal epithelial stem cell treatment patient severe ocular surface disorder . The corneal limbal epithelial stem cell transplant ( CLET ) successful outcome measure improvement vision , maintenance corneal re-epithelisation absence recurrence surface disease subjective improvement symptom .</detailed_description>
	<mesh_term>Eye Injuries</mesh_term>
	<criteria>1 . Male nonpregnant female 18 75 year age . 2 . Written inform consent obtain patient parents/guardian . 3 . Patients unilateral limbal stem deficiency 212 month present follow Conjunctivalisation Absence limbal palisade Vogts Chronic inflammation Persistent recurrent corneal epithelial defect 4 . Patients 212 month conservative treatment . * Diagnostic criterion limbal stem cell deficiency follow : Symptoms decrease vision , redness , watering , photophobia recurrent attack pain Triad sign : conjunctivalisation , neovascularisation chronic inflammation Stippled appearance cunjunctivalised cornea loss palisade Vogt Recurrent persistent epithelial defect Superficial vascularisation , scar , thick fibrovascular pannus , ulceration , melt perforation Patients follow eligible enrollment study : 1 . Pregnant nursing woman woman childbearing potential except postmenopausal , surgically sterile use accepted method ( ) birth control negative pregnancy test . 2 . Participation drug trial patient receive investigational drug within 30 day 5 halflives ( whichever longer ) precede screen phase study . 3 . Those person directly involve conduct study . 4 . Any history severe infection hepatitis , renal , gastrointestinal , endocrine neurological disease . 5 . Evidence corneal stromal scarring , cataract , macular oedema scarring , retinal detachment conjunctival keratinisation 6 . Positive HIV , Hepatitis B , C VDRL 7 . History Pulmonary tuberculosis , hepatitis B , 8 . History alcohol substance abuse 9 . History malignancy within previous 5 year 10 . History organ transplant 11 . Any serious medical condition disability , opinion investigator , would interfere treatment assessment preclude completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>